-
Mashup Score: 0EMJ Cardiology 10 [Supplement 1] 2022 - 2 year(s) ago
a leading expert from the field of cardiology and cardiovascular disease provided their perspectives on Phase II data and the design…
Source: European Medical JournalCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
The findings, from an extension study, are reassuring as a larger phase III trial continues enrolling, researchers say.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet-
#Aficamten Safe, Effective for Up to 6 mth in #HOCM :REDWOOD-HCM OLE Reductions in both resting and Valsalva LVOT gradients were seen within 2 wks of Rx initiation, with continued improvements through up to 24 wks of f/up @TCTMD @MasriAhmadMD @mmamas1973 https://t.co/k2L75jprRC
-
-
Mashup Score: 1Aficamten gains breakthrough designation for obstructive HCM - 2 year(s) ago
Cytokinetics announced that the FDA has granted breakthrough therapy designation for aficamten, a next-generation cardiac myosin inhibitor, for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.The decision is based on the results from the REDWOOD-HCM phase 2 trial of aficamten (Cytokinetics) in patients with symptomatic obstructive HCM, which were presented at the Heart
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: Cytokinetics announced that the #FDA has granted breakthrough therapy designation for #aficamten, a next-generation cardiac myosin inhibitor, for the treatment of symptomatic obstructive hypertrophic cardiomyopathy #CardioTwitter https://t.co/4ANX9Se7HN
-
-
Mashup Score: 3Aficamten gains breakthrough designation for obstructive HCM - 2 year(s) ago
Cytokinetics announced that the FDA has granted breakthrough therapy designation for aficamten, a next-generation cardiac myosin inhibitor, for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.The decision is based on the results from the REDWOOD-HCM phase 2 trial of aficamten (Cytokinetics) in patients with symptomatic obstructive HCM, which were presented at the Heart
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: Cytokinetics announced that the #FDA has granted breakthrough therapy designation for #aficamten, a next-generation cardiac myosin inhibitor, for the treatment of symptomatic obstructive hypertrophic cardiomyopathy #CardioTwitter https://t.co/4ANX9Se7HN
-
-
Mashup Score: 3Aficamten gains breakthrough designation for obstructive HCM - 2 year(s) ago
Cytokinetics announced that the FDA has granted breakthrough therapy designation for aficamten, a next-generation cardiac myosin inhibitor, for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.The decision is based on the results from the REDWOOD-HCM phase 2 trial of aficamten (Cytokinetics) in patients with symptomatic obstructive HCM, which were presented at the Heart
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Cytokinetics announced that the #FDA has granted breakthrough therapy designation for #aficamten, a next-generation cardiac myosin inhibitor, for the treatment of symptomatic obstructive hypertrophic cardiomyopathy #CardioTwitter https://t.co/4ANX9Se7HN
-
-
Mashup Score: 0
Full Results from REDWOOD-HCM Demonstrate Improvements in Biomarkers and Heart Failure Symptoms in Patients with Obstructive Hypertrophic Cardiomyopathy…
Source: GlobeNewswire News RoomCategories: Cardiologists, Latest HeadlinesTweet-
REDWOOD-HCM : Demonstrate Improvements in Biomarkers and HF Symptoms in Patients with #HOCM Treated with #Aficamten https://t.co/FxpOk2hq5N @Cytokinetics #HFSA2021 @NMHheartdoc @DrNasrien @JavedButler1 @BiykemB @iamritu @DrMarthaGulati @RyanTedfordMD @AndrewJSauer https://t.co/TRW2HBWlO3
-
In an interview conducted by EMJ, a leading expert from the field of #cardiology and cardiovascular disease provided their perspectives on Phase II data and the design of the Phase II trial for #aficamten. Learn more: https://t.co/15IVCYZgvp